Clinical trials of durvalumab - TrialResults-center.org

Trial	Studied treatment	Control treatment	patients	ROB	Result	NCT
Head and neck cancer
Hawk ongoing	durvalumab	standard treatment	2L PD-L1 positive		-	NCT02207530
lung cancer (metastatic)
PACIFIC, 2017	durvalumab	placebo	maintenance	Low risk of bias	Conclusive	NCT02125461
ARCTIC PD-L1 negative, 2018	durvalumab + tremelimumab	Standard of Care	3L, PD-L1 negative		-	NCT02352948
NEPTUNE ongoing	durvalumab + tremelimumab	platinum-based CT	1L	Risk of bias	-	NCT02542293
CAURAL ongoing	durvalumab + osimertinib	osimertinib	2L after EGFR TKI, T790M positive	Risk of bias	-	NCT02454933
NCT02273375 ongoing	durvalumab	placebo	adjuvant	Low risk of bias	-	NCT02273375
ARCTIC PD-L1 positive ongoing	durvalumab	Standard of Care	>2L, PDL1 positive	Risk of bias	-	NCT02352948
MYSTIC (combination) ongoing	durvalumab +tremelimumab	Standard of Care	1L	Risk of bias	-	NCT02453282
MYSTIC (monotherapy) ongoing	durvalumab	Standard of Care	1L	Risk of bias	-	NCT02453282
urothelial carcinoma (advanced)
durvalumab phase 1/2	durvalumab	nil	2nd line	Exploratory	-
DANUBE ongoing	durvalumab + tremelimumab	chemotherapy	first line	Low risk of bias	-	NCT02516241

Durvalumab immune checkpoint inhibition Description Results